INEX Innovate Launches epiHERA®, a Step Forward in Early Endometrial Cancer Detection, at the Singapore International Congress of Obstetrics and Gynaecology

2023-08-30

Singapore, August 29, 2023 — INEX Innovate, a pioneering Women’s Life Science Health Innovations group, is pleased to announce the launch of epiHERA® the company’s early endometrial cancer detection technology. epiHERA® was unveiled at the esteemed 2023 Singapore International Congress of Obstetrics and Gynaecology (SICOG), held from August 25th to 27th. With 1 in 10 women suffering from abnormal bleeding during their lifetime and requiring an invasive specialist biopsy procedure to rule out endometrial cancer. By using the widely accepted PAP smear or HPV sampling procedure instead, epiHERA® holds great potential as an adjunct tool to help clinicians right at the clinic. At the core of epiHERA® lies an advanced PCR test designed to identify epigenetic alterations in genes linked to the presence of endometrial cancer. The process begins with a straightforward cervical swab, akin to the sample collection approach used in cervical cancer screening. Following this, genomic DNA extraction takes place, succeeded by bisulfite conversion. The test culminates in real-time PCR analysis targeting hypermethylated CDO1 and CELF4 genes. This streamlined process concludes within approximately six hours. Made in Singapore in collaboration with our partner JH CisPoly, INEX Innovate's epiHERA® technology addresses a crucial gap in current diagnostics by promoting equitable access to testing for vulnerable women. The novel methodology optimizes sample acquisition, significantly decreasing turnaround time from weeks to days. The scalability of molecular PCR testing assures broad accessibility, further amplifying the impact of epiHERA® within the domain of women's health. In validation studies being undertaken with the Chinese University of Hong Kong (CUHK) epiHERA® has shown promising results. CEO of INEX Innovate – Kane Black said “The launch of epiHERA® is a testament not only to a shift in endometrial cancer detection but also underscores INEX Innovate's unwavering dedication to innovative solutions that enable timely interventions and improved patient outcomes. epiHERA® is the latest test launched by our team as we continue our path to being Asia’s pre-eminent women’s life science platform, and has received significant interest from clinicians and lab operators in the region. The launch comes at an exciting time of growth for the company on the back of recent acquisitions in the area as we expand both technology pipelines and geographically across the region.” In a significant move, epiHERA® is now accessible to researchers for validation within their own population cohorts, facilitating diverse applications and a comprehensive understanding of its effectiveness. As SICOG 2023 draws to a close, attendees, including luminaries from the world of Obstetrics and Gynaecology, including maternal-fetal medicine, benign gynaecology, reproductive medicine, and gynaecological oncology, depart with a sense of enthusiasm and anticipation. INEX Innovate's epiHERA® technology is set to redefine the landscape of women's health, and the company remains committed to empowering women and healthcare professionals with tools that transcend boundaries. About INEX Innovate: Entrepreneur led and science backed, 𝐈𝐍𝐄𝐗 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐞 is one of Asia’s fastest growing molecular diagnostics developers and medical laboratory operators. Founded by veteran maternal fetal medicine sINEXalists, INEX is uniquely positioned to identify and address clinically unmet needs within the fetal health and women’s oncology landscape, with a broad commercial portfolio of validated tests and 49 key patents. Through our wholly owned subsidiary iGene LaboratoINEXte Ltd, INEX operates a state of the art Next Generation Sequencing Laboratory that provides diagnostic testing, clinical research (CRO) and infectious testing services. The company has been recognised globally with a number of accolades and awards incFrost & Sullivant & Sullivan, the World Intellectual Property Organisation (WIPO), The Straits Times – Singapore’s Fastest Growing Companies, the Financial Times ranking of 500 of Asia Pacific’s Fastest Growing Companies and the Business Times KPMG Enterprise 50 award, recognising the 50 most enterprising Singapore companies. For more information please visit: or contact Olsen Goh; Olsen.goh@inex.sg